Core Breakthrough - The company Tianhe Bio's AKG and Ca-AKG products have successfully completed the Self-GRAS scientific evaluation under FDA guidelines, becoming the first domestic products to receive GRAS certification through fermentation methods, thus gaining access to the U.S. market [1] - This achievement fills a gap in domestic product process certification and marks a significant step for the company in entering the global nutrition and health market [1] Technical Strength - Tianhe Bio employs a patented whole-cell catalysis method for its CynbioX®AKG, using food-grade glutamic acid bacteria as a carrier, ensuring product safety and reducing impurities while enhancing purity [2] - The company has achieved large-scale production of CynbioX®AKG and CynbioX®Ca-AKG products, positioning itself as a global innovator in AKG applications [2] - The company has obtained multiple important certifications, including KOSHER, FSSC 22000, and HALAL, aligning its technology and quality control with international standards [2] International Standards and Market Expansion - The successful acquisition of the U.S. Self-GRAS certification demonstrates the company's international standards in product development and quality control, laying a solid foundation for expanding into the global nutrition and health market [3] - There is a growing demand for AKG components in anti-aging, sports nutrition, and weight management sectors, and the company is expected to leverage its certification advantages and technological accumulation to gain a competitive edge in the global AKG market [3]

Core Viewpoint - Guohai Securities initiates coverage on Zhonghui Biological-B (02627) with a "Buy" rating, predicting the company will achieve profitability by 2027, leading to a dual boost in performance and valuation known as the "Davis Double Play" [1] Group 1: Company Overview - Zhonghui Biological focuses on innovative vaccine upgrades and has entered the commercialization phase [1] - The company was established in 2015 and is dedicated to the research, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] Group 2: Product Pipeline - The company's core product, Huiliankangxin (Quadrivalent Influenza Virus Subunit Vaccine), has been launched and is expected to generate revenue of 260 million yuan in 2024, a 398% increase year-on-year [2] - The 23-valent pneumococcal polysaccharide vaccine and freeze-dried human rabies vaccine (human diploid cells) have completed Phase I clinical trials [1] Group 3: Market Potential - The domestic influenza vaccine market has significant growth potential, with split vaccines currently dominating market share [2] - The rabies vaccine market is substantial, with approximately 18 to 20 million people in China receiving rabies vaccinations annually [3] Group 4: Technological Advancements - The company has developed a leading core technology platform that supports both traditional vaccine upgrades and innovative vaccine development, with a pipeline of 11 vaccines under research [4] - The in-development human diploid cell rabies vaccine has shown good safety in Phase I trials and is designed for convenient administration [3]

近日，亦诺微医药港股IPO申请获得受理，招股书正式公开。亦诺微致力于开发新型溶瘤免疫疗法和工 程化外泌体疗法，已经建立起包括2款溶瘤病毒疗法和5款外泌体疗法的管线。 招股书显示，亦诺微医药溶瘤病毒疗法MVR-T3011已经与上海医药（601607）达成合作开发协议，并 已经收到2000万元预付款及3000万元专利许可授权款。 ...

Core Viewpoint - Guohai Securities initiates coverage on Zhonghui Biological-B (02627) with a "Buy" rating, predicting the company will achieve profitability by 2027, leading to a dual boost in performance and valuation known as the "Davis Double" [1] Group 1: Company Overview - Zhonghui Biological, established in 2015, focuses on the research, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company has launched its quadrivalent influenza virus subunit vaccine, with the 23-valent pneumococcal polysaccharide vaccine and freeze-dried human rabies vaccine having completed Phase I clinical trials [1] Group 2: Product Highlights - The Huierkangxin quadrivalent influenza virus subunit vaccine offers higher safety and good immune effects, targeting the high-end influenza vaccine market [1] - The domestic market for influenza vaccines has significant growth potential, with the quadrivalent subunit vaccine being the first and only of its kind in China, providing comprehensive protection and lower adverse reaction risks compared to split vaccines [1] - The product is expected to generate revenue of 260 million RMB in 2024, representing a 398% year-on-year increase, and is currently in a rapid growth phase [1] Group 3: Rabies Vaccine Development - The company is developing a human diploid cell rabies virus vaccine, which is based on WHO's gold standard technology, aiming to capture a high-quality rabies vaccine market worth billions [2] - With approximately 18 to 20 million people in China receiving rabies vaccinations annually, the company’s vaccine shows good safety in Phase I trials and offers convenient administration options [2] - The Phase III clinical trial for the rabies vaccine has been initiated as of December 2025 [2] Group 4: Research and Development Pipeline - The company has established a leading core technology platform that supports both traditional vaccine upgrades and innovative vaccine development, with a total of 11 vaccines in the research pipeline [2] - The focus is on unmet public health needs and high commercial potential indications, with the company actively developing additional vaccines to address market gaps [2]

1月15日，益方生物跌5.1%，截至发稿，报30.12元/股，成交3.34亿元，换手率2.59%，总市值174.20亿 元。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室,香港 湾仔皇后大道东183号合和中心46楼，成立日期2013年1月11日，上市日期2022年7月25日，公司主营业 务涉及创新药物的研发、生产和销售。主营业务收入构成为：技术授权和技术合作收入100.00%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，富国基金旗下1只基金重仓益方生物。富国生物医药科技混合型A（006218）三季度减持 13.03万股，持有股数54.23万股，占基金净值比例为3.11%，位居第九大重仓股。根据测算，今日浮亏 损失约87.86万元。 富国生物医药科技混合型A（006218）成立日期2019年3月12日，最新规模4.86亿。今年以来收益 11.48%，同类排名638/ ...

Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock increase of over 7%, currently at 46.5 HKD with a trading volume of 18.84 million HKD, following a recommendation from health experts for annual flu vaccinations for all individuals over 6 months old without contraindications [1] Group 1: Product and Market Performance - Huiliankangxin is the first and only quadrivalent subunit flu vaccine in China, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions compared to split vaccines [1] - The product was approved for domestic market launch in 2023, targeting individuals aged 3 and above, with plans to expand to those over 6 months old by 2025 [1] - Projected revenue for 2024 is 260 million RMB, representing a year-on-year growth of 398% [1] Group 2: Company Development and Strategy - The company has developed a comprehensive vaccine development support platform and proprietary technology platform, aligning with international trends through years of research [1] - The company is advancing both innovative vaccine research and traditional vaccine upgrades, creating a rich pipeline of vaccines [1] - In addition to the quadrivalent flu vaccine and human diploid cell rabies vaccine, the company is actively developing 11 other vaccines to address unmet public health needs and market gaps [1]

Group 1 - The core point of the article is that China Biologic Products announced the acquisition of 100% equity in Hejia for a total price of 1.2 billion yuan, with approximately 1.1 billion yuan paid in cash and the remaining 97 million yuan paid in new shares [1] - Hejia is a clinical-stage biotech company focused on siRNA technology, currently having four clinical-stage projects targeting Lp(a), ApoC3, THRbeta, and HBV, along with over ten preclinical candidates [1] - This acquisition marks the third transaction by China Biologic Products in two years, and Goldman Sachs believes that as siRNA technology becomes an important innovation model for chronic disease treatment, this acquisition will enhance the company's R&D pipeline in cardiovascular, metabolic, and liver disease areas, creating synergies with existing products [1] Group 2 - Goldman Sachs has given China Biologic Products a "Buy" rating with a target price of 6.19 HKD [1]

Group 1 - The core viewpoint of the article is that China Biopharmaceutical has announced the acquisition of private biotech company Hygieia, which specializes in small interfering RNA (siRNA) drugs, with a maximum base consideration of 1.2 billion yuan [1] - This acquisition will enable China Biopharmaceutical to establish a new generation of cardiovascular innovation pipeline and strengthen its presence in weight management and metabolic disease sectors, while also expanding into the chronic disease management market [1] - The report suggests that this acquisition enhances China Biopharmaceutical's innovation capabilities and licensing potential, further solidifying its position as a leader among Chinese innovative pharmaceutical companies [1] Group 2 - The target price for China Biopharmaceutical is set at 10.8 Hong Kong dollars, with a "buy" rating assigned [1]

Core Insights - Fudan University has established a strong growth momentum in its collaborative laboratories, planning to build 40 new labs by 2025 with a total contract amount exceeding 600 million yuan, doubling the scale compared to 2024 [3] - The focus on artificial intelligence has led to the establishment of 20 new labs in this field, representing half of the total new labs for the year [3] Group 1: Challenges and Opportunities in University-Industry Collaboration - The natural conflict in university-industry collaboration arises from differing goals: companies seek short-term results while universities focus on long-term theoretical breakthroughs [4] - Collaborative laboratories provide a solution by combining academic exploration with industrial resources, allowing for the validation of research and injecting new technological vitality into companies [5] Group 2: Successful Case Studies - Shanxi Jinbo's collaboration with Fudan University led to the development of HPV protein and human-derived collagen materials, achieving over 1 billion yuan in annual sales, demonstrating a successful technology-to-market transition [5] - The Fudan University Intelligent Robotics Research Institute has established eight collaborative labs with leading companies, creating a symbiotic relationship that enhances data accumulation for AI model development [6] Group 3: Innovative Collaboration Models - The collaborative labs are not limited to traditional product development but focus on future innovations, such as sustainable materials and advanced battery technologies [8] - The integration of diverse stakeholders, including government and private entities, into the collaborative framework enhances resource sharing and risk management [11] Group 4: Mechanisms for Enhancing Collaboration - A one-stop service model has been introduced to streamline project approval processes, significantly reducing the time required for project initiation [11] - A competitive distribution mechanism for doctoral programs prioritizes collaboration with external enterprises, fostering a dual flow of talent between academia and industry [11] - A comprehensive evaluation and incentive system encourages researchers to engage in practical applications, shifting the focus from theoretical research to technology commercialization [11]

1月15日，天眼查融资历程显示，艾里奥斯生物科技（上海）有限公司近日获得"Pre-B轮"融资，涉及融 资金额逾亿人民币，投资机构为【首发】艾里奥斯完成逾亿元pre-B轮融资，以自主创新的膜材料技 术，打造生物制药过滤领域国产新范本。 天眼查信息显示，艾里奥斯生物科技（上海）有限公司的股东为：上海谦牧生物科技合伙企业（有限合 伙）、上海如晋生物科技合伙企业（有限合伙）、西藏龙磐中小企业发展基金股权投资合伙企业（有限 合伙）、健卫有限公司、厦门经禾里一号股权投资合伙企业（有限合伙）。 来源：市场资讯 通过天眼查大数据分析，艾里奥斯生物科技（上海）有限公司共对外投资了4家企业，知识产权方面有 商标信息70条，专利信息38条，此外企业还拥有行政许可19个。 资料显示，艾里奥斯生物科技（上海）有限公司法定代表人为贾启军，成立于2021年，位于上海市，是 一家以从事批发业为主的企业。企业注册资本3902.7749万人民币，并已于2026年完成了Pre-B轮，交易 金额逾亿人民币。 ...